Skip to main content
XNCR $35.40 -4.56%
XNCR logo
XNCR · Xencor Inc
Track XNCR — free
$35.40 -1.69 (-4.56%) At close · Nov 16 Q4 2023 earnings call transcript
Market Cap
$2.66B
Shares
75.04M
Volume · Nov 16 1.03M Avg daily vol (3M) 1.55M
All webcasts

Earnings call · FY2026 Q3

Xencor Inc (XNCR) Q3 2026 Earnings Call

Concluded Oct 26, 2026
Oct 26, 2026
Period
FY2026 Q3
Runtime
—
Sources
3 artifacts
Revenue $116.52M +454.9% YoY
Diluted EPS $0.50
Net income $39.44M
Open full screen Slides 47 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 4, 2026
Xencor reported third-quarter revenue of $116.5 million and net income of $39.4 million, versus $21.0 million revenue and a $6.0 million net loss in 2025. It held $555.7 million in cash, cash equivalents and marketable debt securities.
10-Q report · filed Nov 4, 2026
XmAb819’s selected 400 mcg/kg IV dose produced five confirmed partial responses among 11 efficacy-evaluable patients, a 45.5% confirmed objective response rate. The Alexion settlement provides $105.0 million and ends U.S. Ultomiris royalties.

The audio replay and transcript follow the call.

Research coverage

3 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Quarter detail

How the reported period landed and where the business moved.

Revenue · products & services

Royalty$87.52M +316.8% YoY
Milestone$29.00M
License$0
Full-screen source Call document